Exact Sciences awards $525K in grants to improve CRC screening

By LabPulse.com staff writers

September 22, 2022 -- Cancer screening and diagnostic test provider Exact Sciences on Thursday announced it has awarded $525,000 in grants to eight federally qualified health centers focused on improving colorectal cancer (CRC) screening rates in vulnerable populations.

Exact's Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) program provided the grant funding. Awardees will use the funds to implement evidence-based and informed intervention strategies proven to increase colorectal cancer screening rates, the firm said.

The strategies include supporting screening recovery after COVID-19, improving clinic practices to assist patients with the screening process, working with pharmacists to increase access to screening options, and enhancing patient navigation efforts, Exact said.

After organizations submitted applications to Exact, grant recipients were chosen based on the strength of the application and the alignment to the FOCUS program objectives, without regard to potential commercial relationships, Exact said.

The eight awardees are the following:

  • Access Community Health Center in Madison, WI
  • AtlantiCare Health Services in Atlantic City, NJ
  • Community HealthCare Network in New York, NY
  • Angeles Community Health Center in Los Angeles, CA
  • Mariposa Community Health Center in Santa Cruz County, AZ
  • Mount Sinai Internal Medicine Associations in New York, NY
  • Mountain Park Health Center in Phoenix, AZ
  • San Joaquin Health Center in Stockton, CA

Natera presents colorectal, breast cancer data at ESMO 2022
Natera on Monday announced data for its molecular residual disease (MRD) test, Signatera, presented in four abstracts at the European Society for Medical...
ESMO study shows microbiome potential for CRC detection
Universal Diagnostics on Monday announced the results of a proof-of-principle study demonstrating that the analysis of microbiome signatures in plasma...
MDxHealth buys Exact Sciences’ prostate cancer business
MDxHealth has acquired the Oncotype DX GPS (genomic prostate score) business from Genomic Health, an Exact Sciences subsidiary, for $100 million.
Exact Sciences Q2 revenues rise 20%
Exact Sciences on Tuesday reported a 20% year-over-year increase in second quarter revenues. For the quarter ended June 30, the firm posted revenues of...
Exact Sciences supports CMS screening policy changes
Exact Sciences, maker of Cologuard, a DNA-based at-home screening test for colorectal cancer, announced its support on Friday for changes proposed by...

Copyright © 2022 LabPulse.com

Last Updated mp 9/22/2022 12:11:47 PM